Atea posts late-stage trial win for hepatitis C drug (AVIR)
· seekingalpha.com
Atea Pharmaceuticals (AVIR) stock dips despite a a late-stage trial win for the company's lead candidate BEM/RZR against chronic hepatitis C infection. Read more here.
Atea Pharmaceuticals (AVIR) traded lower on Tuesday despite the company’s announcement of a late-stage trial win for its lead candidate BEM/RZR against chroni...